AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Thecentersquare

Published November 13, 2026 · Updated November 14, 2026

Trump administration advances ibogaine, other experimental mental health treatments

Read the full story at Thecentersquare

They argued that psychedelic drugs could help fill a gap in existing treatment options by providing faster-acting and longer-lasting relief for some.

Post on X

Share this story

Surfaced by 2 Google Alerts

Psychedelics south america
Ibogaine